Miconazole - Stiefel Laboratories

Drug Profile

Miconazole - Stiefel Laboratories

Alternative Names: Bebektin; Daktozin; Vusion; Zimycan

Latest Information Update: 07 Sep 2016

Price : $50

At a glance

  • Originator Johnson & Johnson
  • Developer Johnson & Johnson; Stiefel Laboratories
  • Class Antifungals; Imidazoles; Small molecules
  • Mechanism of Action Cell membrane modulators; Cholesterol synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Candidiasis

Most Recent Events

  • 08 Oct 2013 Zimycan® is no longer licensed to Smith & Nephew
  • 03 Jun 2013 Miconazole licensed to Renaissance Acquisition Holdings in the USA
  • 21 Dec 2012 Healthpoint Biotherapeutics has been acquired by Smith & Nephew
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top